IN2014MN01486A - - Google Patents
Info
- Publication number
- IN2014MN01486A IN2014MN01486A IN1486MUN2014A IN2014MN01486A IN 2014MN01486 A IN2014MN01486 A IN 2014MN01486A IN 1486MUN2014 A IN1486MUN2014 A IN 1486MUN2014A IN 2014MN01486 A IN2014MN01486 A IN 2014MN01486A
- Authority
- IN
- India
- Prior art keywords
- hcv
- inhibitors
- solvates
- meaning
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195841 | 2011-12-28 | ||
| EP12152267 | 2012-01-24 | ||
| PCT/EP2012/076942 WO2013098320A1 (en) | 2011-12-28 | 2012-12-27 | Quinazolinone derivatives as hcv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01486A true IN2014MN01486A (ja) | 2015-04-24 |
Family
ID=47505013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1486MUN2014 IN2014MN01486A (ja) | 2011-12-28 | 2012-12-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9382261B2 (ja) |
| EP (1) | EP2797913B1 (ja) |
| JP (2) | JP6199891B2 (ja) |
| CN (1) | CN104169271B (ja) |
| AU (1) | AU2012360910B8 (ja) |
| BR (1) | BR112014016007A8 (ja) |
| CA (1) | CA2858646A1 (ja) |
| ES (1) | ES2601461T3 (ja) |
| IN (1) | IN2014MN01486A (ja) |
| MX (1) | MX348127B (ja) |
| RU (1) | RU2014131017A (ja) |
| WO (1) | WO2013098320A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2680507A1 (en) | 2006-10-13 | 2008-04-24 | Xtl Biopharmaceuticals Ltd. | Compounds and methods for treatment of hcv |
| EP2097405A2 (en) | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2745119A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CN104163816A (zh) * | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
| WO2011004276A1 (en) * | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| CA2791630A1 (en) * | 2010-03-04 | 2011-09-09 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of hcv replication |
| US8815849B2 (en) * | 2010-07-26 | 2014-08-26 | Janssen R&D Ireland | Hetero-bicyclic derivatives as HCV inhibitors |
| US9126986B2 (en) * | 2011-12-28 | 2015-09-08 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
-
2012
- 2012-12-27 RU RU2014131017A patent/RU2014131017A/ru not_active Application Discontinuation
- 2012-12-27 MX MX2014008042A patent/MX348127B/es active IP Right Grant
- 2012-12-27 EP EP12810312.4A patent/EP2797913B1/en not_active Not-in-force
- 2012-12-27 ES ES12810312.4T patent/ES2601461T3/es active Active
- 2012-12-27 IN IN1486MUN2014 patent/IN2014MN01486A/en unknown
- 2012-12-27 CA CA2858646A patent/CA2858646A1/en not_active Abandoned
- 2012-12-27 US US14/368,511 patent/US9382261B2/en not_active Expired - Fee Related
- 2012-12-27 WO PCT/EP2012/076942 patent/WO2013098320A1/en active Application Filing
- 2012-12-27 BR BR112014016007A patent/BR112014016007A8/pt not_active IP Right Cessation
- 2012-12-27 CN CN201280065174.5A patent/CN104169271B/zh not_active Expired - Fee Related
- 2012-12-27 AU AU2012360910A patent/AU2012360910B8/en not_active Ceased
- 2012-12-27 JP JP2014549464A patent/JP6199891B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-28 JP JP2017146186A patent/JP2018012699A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013098320A1 (en) | 2013-07-04 |
| EP2797913A1 (en) | 2014-11-05 |
| AU2012360910B8 (en) | 2017-02-02 |
| CN104169271A (zh) | 2014-11-26 |
| ES2601461T3 (es) | 2017-02-15 |
| MX2014008042A (es) | 2014-08-21 |
| AU2012360910B2 (en) | 2017-01-05 |
| CN104169271B (zh) | 2017-04-05 |
| EP2797913B1 (en) | 2016-08-17 |
| AU2012360910A1 (en) | 2014-06-26 |
| US20140378485A1 (en) | 2014-12-25 |
| JP6199891B2 (ja) | 2017-09-20 |
| BR112014016007A8 (pt) | 2017-07-04 |
| JP2018012699A (ja) | 2018-01-25 |
| JP2015503537A (ja) | 2015-02-02 |
| CA2858646A1 (en) | 2013-07-04 |
| MX348127B (es) | 2017-05-26 |
| AU2012360910A8 (en) | 2017-02-02 |
| RU2014131017A (ru) | 2016-02-20 |
| US9382261B2 (en) | 2016-07-05 |
| BR112014016007A2 (pt) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12018501812A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12016500723B1 (en) | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12016500027B1 (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| MX2015011229A (es) | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. | |
| PH12015500780A1 (en) | Rsv antiviral compounds | |
| MX2015015771A (es) | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. | |
| IN2014MN01465A (ja) | ||
| MX353412B (es) | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UA115069C2 (uk) | Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| IN2014MN01486A (ja) | ||
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |